OGEN

Oragenics Inc

AMEX

Add Alert

OGEN

Oragenics Inc

AMEX

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Monksdream PremiumMember

04/06/24 4:23 PM

Post #834

OGEN under $2

Monksdream PremiumMember

03/18/24 2:28 PM

Post #833

OGEN 10Q due 3/19

willlbone

01/31/24 2:48 PM

Post #832

China Dump

JDCruz

11/02/23 9:47 AM

Post #831

News just hit! Oragenics Issues Update to Shareholders:
https://www.otcmarkets.com/stock/OGEN/news/story?e&id=2676834

Bullish

JDCruz

10/30/23 11:59 AM

Post #830

OGEN steady rise looks like this biotech is ready to run!

retired early Free

06/02/23 3:53 PM

Post #829

Will this turd float to the surface? :)

retired early Free

03/01/23 1:46 PM

Post #827

Re: #826: @Nathan123456 - Don't madder they will short it down to nothing

Maybe not. :)

Nathan123456 Free

12/22/22 5:32 PM

Post #826

Don't madder they will short it down to nothing

retired early Free

12/22/22 9:35 AM

Post #825

Surfs up. ::)

BEIJING BILL Free

08/17/22 12:51 PM

Post #824

Chart setup perfectly here -> time is koming for the super spike

https://stockcharts.com/h-sc/ui?s=ogen

retired early Free

05/27/22 1:06 PM

Post #823

Hey whatever it takes to see it rise to the moon but wow hats off to your sacrifice. :)

THEMASTERS_SON Free

04/04/22 2:56 PM

Post #822

,,,,,,,I’m out

unpathedhaunt Free

03/22/22 11:00 AM

Post #821

3/22 Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

"“We are thrilled to have begun this pivotal study with Frontage, a premier drug development contract research organization, and are thankful to the acceleration Frontage has offered our important IND-enabling study. We believe the results from this rabbit toxicology study will support our development strategy for our intranasal COVID-19 vaccine candidate, NT-CoV2-1. The intranasal delivery route is particularly relevant as it may further reduce transmission of the virus and provide a needle-free delivery option. The findings from this preclinical toxicology study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration,” said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics."

https://ir.oragenics.com/press-releases/detail/142

BEIJING BILL Free

03/03/22 9:24 AM

Post #820

Re: #819: @retired early - Looks like word is getting out. :)

KABOOM !! ve got movement!!

retired early Free

02/25/22 12:20 PM

Post #819

Looks like word is getting out. :)

retired early Free

01/04/22 2:11 PM

Post #818

I agree. The buy consensus is at 83%.3 days ago. I think info is near. :)

Nathans123 Free

01/03/22 8:14 PM

Post #817

HUGE insider buy

TheFinalCD PremiumMember

12/20/21 11:51 AM

Post #816

Re: #815: @shurtha2000 - lets get this back over $1

OGEN HOD

shurtha2000 Free

12/20/21 10:50 AM

Post #815

lets get this back over $1

alisher

12/20/21 8:46 AM

Post #814

Oragenics (OGEN) Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

Agreement extends current licensing and collaboration agreement to include rapid production of Omicron-specific intranasal vaccine candidates

TAMPA, Fla., December 20, 2021--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant. The NRC cell expression technologies provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines. The NRC technologies, developed with support from the NRC’s Pandemic Response Challenge program, will expedite the evaluation of an Omicron-specific Terra-CoV-2 candidate in preclinical and clinical studies.

"Oragenics is well-positioned to develop an Omicron-specific intranasal vaccine thanks to our successful, on-going collaboration with the NRC," said Frederick W. Telling, Ph.D., Oragenics’ Executive Chairman. "We had anticipated the need for rapid development of COVID-19 vaccine candidates against new variants and can leverage the NRC cell expression platform to address Omicron and future variants."

Oragenics recently demonstrated the protection of hamsters against SARS-CoV-2 with the intranasal Terra-CoV-2 candidate, which strongly supports the further development into an IND-enabling GLP toxicology study and a first-in-human Phase 1 clinical study.

https://finance.yahoo.com/news/oragenics-extends-collaboration-national-research-130000929.html

alisher

12/04/21 5:48 PM

Post #813

Oragenics Announces Positive COVID-19 Challenge Study Results

Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.

Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. The vaccines delivered by intranasal and intramuscular routes generated immune responses as measured by multiple assays.

"The very positive results from this hamster challenge study fully support our further development of either the intranasal or intramuscular routes of administration, however we plan to focus on the intranasal delivery route for the Terra CoV-2 vaccine due to the relative lack of competition and anticipated advantages of intranasal vaccine delivery, such as reducing viral transmission, needle-free administration, and ease of distribution, as well as the potential for conferred mucosal immunity which is presently being studied. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the second quarter of 2022, and should facilitate advancement of the program into human clinical studies," said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.

https://finance.yahoo.com/news/oragenics-announces-positive-covid-19-130000711.html

Renegade Rich Free

12/01/21 11:59 AM

Post #812

News!

Mountainman5 Free

09/12/21 8:27 AM

Post #811

ORAGENICS is really on a good way to achieve soon $ 10 or more!!!!!!!!!!!!!!!!!!!!!!!!!!

retired early Free

08/30/21 10:01 AM

Post #810

Re: #809: @oakrock - How does that help OGEN?

Opps good call. I own both and posted on the wrong board. :)

oakrock

08/26/21 1:44 AM

Post #809

Re: #808: @retired early - Qiagen has received emergency use authorization from the

How does that help OGEN?

retired early Free

08/06/21 1:28 PM

Post #808

Qiagen has received emergency use authorization from the U.S. Food and Drug Administration for its QIAreach SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results. :)

oakrock

07/28/21 6:37 PM

Post #807

Re: #806: @GREGG THE GREEK - Been a nice atm.

OGEN will be a player....opportunity knocks.

GREGG THE GREEK PremiumMember

07/28/21 9:16 AM

Post #806

Re: #805: @Lowhndcpr - What will happen today? Morning dip into low

Been a nice atm.

OGEN

Lowhndcpr

07/28/21 9:02 AM

Post #805

What will happen today? Morning dip into low 70s to add?
Every time this stock runs….she sells off Next couple days. We shall see

MADDSTACKER Free

07/27/21 2:43 PM

Post #804

Re: #803: @shurtha2000 - $100-$200M from Canadian govt funding ?

Here comes eod volume

shurtha2000 Free

07/27/21 11:07 AM

Post #803

$100-$200M from Canadian govt funding ?

MADDSTACKER Free

07/27/21 10:57 AM

Post #802

Re: #801: @retired early - EPIC :)

Should thin out soon

retired early Free

07/27/21 9:36 AM

Post #801

EPIC :)

MADDSTACKER Free

07/27/21 8:46 AM

Post #800

Re: #799: @bigbut - Big day looming here after OGEN announcement of

Could be epic

bigbut

07/27/21 8:19 AM

Post #799

Re: #798: @Lowhndcpr - Nice day here. Need to get back to

Big day looming here after OGEN announcement of work with Canadian Government on fast track vaccine alternatives.

Lowhndcpr

07/19/21 4:05 PM

Post #798

Nice day here. Need to get back to a buck soon

420man

06/07/21 6:48 PM

Post #797

O-0

dancy

05/18/21 2:32 PM

Post #796

Re: #795: @ClayTrader - * * $OGEN Video Chart 04-23-2021 * *

OGEN cover time smile

ClayTrader Free

04/23/21 6:38 PM

Post #795

* * $OGEN Video Chart 04-23-2021 * *

Link to Video - click here to watch the technical chart video

retired early Free

04/23/21 12:14 PM

Post #794

It's all about the therapeutics, peutics, peutics. :)

trendzone

04/09/21 1:45 PM

Post #793

Re: #791: @oxnous - Time to.move up

It's time for the CEO to get his head out of his toxic azz.

DMOST

04/09/21 4:07 AM

Post #792

Re: #791: @oxnous - Time to.move up

Past time.................But I can wait.

GO OGEN

"PEACE"

oxnous

04/08/21 9:24 PM

Post #791

Re: #788: @DMOST - Filled at the gap............

Time to.move up

Golden Cross Free

04/06/21 8:53 PM

Post #790

Re: #776: @iluvkush - Run?

Sorry, spike....

geocam

03/30/21 4:40 PM

Post #789

$OGEN Meandering up from the morning low on low volume. Any upcoming catalysts expected?

https://www.stockscores.com/charts/charts/?ticker=OGEN

below average volume
https://ih.advfn.com/stock-market/AMEX/oragenics-OGEN/historical

DMOST

03/25/21 6:17 AM

Post #788

Filled at the gap............

GO OGEN

"PEACE"

trendzone

03/24/21 5:54 PM

Post #787

Breaking news OGEN upgraded with a $2.75 PT

After-Hours Stock Movers 03/24: (RH) (OGEN) (FUL) Higher; (RAD) (EVFM) (KBH) Lower (more...)

March 24, 2021 5:40 PM

?

After-Hours Stock Movers

Rite Aid Corporations (NYSE: RAD) 17.9% LOWER; fourth quarter 2021 financial results were significantly impacted by a soft cough, cold and flu season, ongoing impacts related to COVID-19 and challenging weather conditions. As a result, the Company is updating its guidance for the fiscal year ended February 27, 2021.

Do this one thing with your money by April 30th

Sponsored By Stansberry Research

The next few weeks could affect your wealth for the next decade. Millions of Americans will be taken by surprise. Here’s what’s coming.

Evofem Biosciences, Inc. (NASDAQ: EVFM) 11.2% LOWER; announced that it intends to offer and sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering

RH (NYSE: RH) 9.4% HIGHER; reported Q4 EPS of $5.07, $0.31 better than the analyst estimate of $4.76. Revenue for the quarter came in at $812.4 million versus the consensus estimate of $797.27 million.

Oragenics (NYSE: OGEN) 8% HIGHER; Ascendiant Capital assumes coverage with a Buy rating and a price target of $2.75.

H.B. Fuller (NYSE: FUL) 6.2% HIGHER; reported Q1 EPS of $0.66, $0.18 better than the analyst estimate of $0.48. Revenue for the quarter came in at $726 million versus the consensus estimate of $680.98 million.

KB Home (NYSE: KBH) 5.8% LOWER; reported Q1 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. Revenue for the quarter came in at $1.14 billion versus the consensus estimate of $1.21 billion.

D8 Holdings Corp (NYSE: DEH) 2.7% HIGHER; Vicarious Surgical, a developer of medical robot tech that's backed by Bill Gates, is in talks to go public through a merger with blank-check firm D8 Holdings Corp (NYSE: DEH), according to a report from Bloomberg, citing a person with knowledge of the matter.

Full House Resorts, Inc. (Nasdaq: FLL) 2.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Wall Street Connected: Oriental Culture Holdings

Wall Street Connected: Oriental Culture Holdings

Latest Videos

?

Wall Street Connected: Oriental Culture Holdings

?

Looking at 10-Year Yields

?

Higher Yields, Stronger Dollar?

?

Categories

Special Reports

?

?

DMOST

03/10/21 7:15 AM

Post #786

Re: #785: @ClayTrader - * * $OGEN Video Chart 03-09-2021 * *

The gap set around 85 will have to eventually closed and then the share price recover before another substantial move upward?

Waiting to see what event initialized that move.....Another share offering, warrants, sells?

WE WILL WAIT TOO SEE.........

'peace'

However, more positive news trumps all...

ClayTrader Free

03/09/21 4:57 PM

Post #785

* * $OGEN Video Chart 03-09-2021 * *

Link to Video - click here to watch the technical chart video

retired early Free

03/09/21 1:11 PM

Post #784

Onward and upward. :)

Older

Oragenics Inc (OGEN)

Followers	76	Posters	199
Posts (Today)	0	Posts (Total)	834
Created	01/29/13	Type	Free
Moderators

ORAGENICS - NYSE Market

https://www.oragenics.com/

""Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.""

https://www.oragenics.com/about

Management Team

Alan Joslyn, Ph.D.

President and Chief Executive Officer

Dr. Joslyn was a partner in Lazarus Pharmaceuticals. Prior to that he served as the Chief Executive Officer and Director of several privately held companies including Edusa Pharmaceuticals and Sentinella Pharmaceuticals and prior to that he was the Senior Vice-President Research and Development of Penwest Pharmaceuticals and also held senior drug development positions with Johnson & Johnson.

Michael Sullivan

Chief Financial Officer

Mr. Sullivan has served as our interim principal executive officer since October 30, 2014 and served as our Chief Financial Officer, Secretary and Treasurer since February 6, 2012. Mr. Sullivan has held senior level financial positions for several publicly and privately held businesses including Utek Corporation, eANGLER, and HSN Direct International Limited. Most recently, he was the Group Financial Officer for the Investigative Services and Litigation Consulting Services segment of First Advantage Corporation. Mr. Sullivan is a Florida Certified Public Accountant. He graduated from the Florida State University with a Bachelor of Science in Accounting and a Master of Business Administration.

Dr. Martin Handfield

Senior Vice President of Discovery Research

Dr. Handfield is, the Company’s Senior Vice President of Discovery Research and previously has served as our Director of Research and Development. Prior to joining our Company, Dr. Handfield held a position as Tenured Associate Professor at the Center for Molecular Microbiology and the Department of Oral Biology at the University of Florida College of Dentistry, where he co-invented IVIAT and co-founded ivi Gene Corp. and Epicure Corp. to commercialize this and related technologies. Dr. Handfield holds a B.S. degree in Biochemistry, and a MS degree and PhD in Microbiology and Immunology from the Université Laval College of Medicine in Canada, and did postdoctoral training at the University of Florida.

https://www.oragenics.com/about/management-team

--------------------------------------------------------------------------------------------------------------------------------------------

OTC - NEWS

Press Releases

Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant

January 7, 2021

Oragenics Announces Closing of $6.5 Million Registered Direct Offering

December 29, 2020

Oragenics, Inc. Announces $6.5 Million Registered Direct Offering

December 24, 2020

Oragenics Announces Closing of $6.0 Million Underwritten Public Offering

November 24, 2020

Oragenics Prices $5.25 Million Common Stock Offering

November 20, 2020

Oragenics Announces Proposed Underwritten Public Offering

November 19, 2020

FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine

October 6, 2020

Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

September 28, 2020

Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference

September 11, 2020

Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

August 20, 2020

See this link to read above Press Release or see more - https://www.oragenics.com/news-media/press-releases

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------